Reimagining the future of vaccines
We are using biotechnology for a novel approach to vaccine development for people around the world
Game-changing innovation to improve access
KBP’s clinical-stage biotech development platform targets speed and innovations in the vaccine manufacturing process with the ultimate goal of increasing patient access to critical vaccines.
Disruptive science at speed and scale
Our plant-based production platform and proprietary conjugation system is highly scalable and able to support rapid production of vaccine antigens.
Rapid protein production
Our proprietary vaccine platform technology, the Tobacco Mosaic Virus (TMV), combined with our manufacturing system has the potential to produce pharmaceutical-grade proteins in a few weeks. This rapid production speed could allow later identification of a virus strain which could enable more people to get the right vaccine faster.
Novel conjugation
We use a novel vector or carrier, the Tobacco Mosaic Virus (TMV), to develop our vaccines. In development, we chemically attach a protein representing the pathogen to TMV. Once the chemical attachment has taken place, the vaccine’s active ingredient has been created and it is then formulated into the final vaccine drug product.
55000 ft2
Automated indoor plant growth room
Weeks not months
Antigens can be rapidly produced
Uses Nicotiana benthamiana plant to produce the proteins used in vaccine development